Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: An EAACI Position Paper

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 7, 2014, Pages 854-867

  Pfaar, O ^a   Demoly, P ^b,c   Gerth Van Wijk, R ^d   Bonini, S ^e   Bousquet, J ^b,f   Canonica, G W ^g   Durham, S R ^h   Jacobsen, L ⁱ   Malling, H J ^j   Mosges R ^k   Papadopoulos, N G ^l,m   Rak, S ⁿ   Rodriguez Del Rio, P ^o   Valovirta, E ^p,q   Wahn, U ^r   Calderon, M A ^h  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^g UNIVERSITY OF GENOA   (Italy)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

ⁱ Allergy Learning and Consulting   (Denmark)

^j GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^k UNIVERSITY OF COLOGNE   (Germany)

^l UNIVERSITY OF ATHENS   (Greece)

^m UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁿ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^o HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^p UNIVERSITY OF TURKU   (Finland)

^q Suomen Terveystalo Allergy Clinic   (Finland)

^r CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

allergen immunotherapy; clinical endpoints; clinical outcomes; combined symptom and medication score; randomized controlled trials

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; RECOMBINANT ALLERGEN; ALLERGEN;

ALLERGEN IMMUNOTHERAPY; ALLERGIC RHINOCONJUNCTIVITIS; ARTICLE; CLINICAL IMMUNOLOGY; DISEASE CONTROL; HUMAN; IMMUNOTHERAPY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; RHINOCONJUNCTIVITIS; STANDARDIZATION; SUBLINGUAL IMMUNOTHERAPY; VISUAL ANALOG SCALE; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION; IMMUNOLOGY; PRACTICE GUIDELINE; RHINITIS, ALLERGIC; STANDARDS;

ALLERGENS; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; RHINITIS, ALLERGIC;

EID: 84902083555     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12383     Document Type: Article

References (98)

1. Bousquet J, Van Cauwenberge P, Khaltaev N,. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (Suppl 5): S147-S334.
2. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl 86): 8-160. (Pubitemid 351357811)
3. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). ICH E 6: Guidance for Industry. Good Clinical Practice: Consolidated Guidance. 1996.
4. The European Agency for the Evaluation of Medicinal Products (EMA). ICH E 9: Note for Guidance on Statistical Principles for Clinical Trials (CPMP/ICH/363/96) 1998.
5. U.S. Department of Health and Human Serviced, FDA Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Allergic Rhinitis: Clinical Development Programs for Drug Products. Draft Guidance. 2000.
6. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases. 2008.
7. Calderon MA, Eichel A, Makatsori M, Pfaar O,. Comparability of subcutaneous and sublingual immunotherapy outcomes in allergic rhinitis clinical trials. Curr Opin Allergy Clin Immunol 2012; 12: 249-256.
8. Pfaar O, Kleine-Tebbe J, Hormann K, Klimek L,. Allergen-specific immunotherapy: which outcome measures are useful in monitoring clinical trials? Immunol Allergy Clin North Am 2011; 31: 289-309.
9. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62: 317-324.
10. Wilson AM, O'Byrne PM, Parameswaran K,. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004; 116: 338-344. (Pubitemid 38230294)
11. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466-476.
12. Canonica GW, Compalati E,. Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies. Clin Exp Immunol 2009; 158: 260-271.
13. Clark J, Schall R,. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy 2007; 62: 1023-1028. (Pubitemid 47220978)
14. Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2011; 10: CD001431.
15. Drug and Therapeutics Bulletin. An introduction to patient decision aids. BMJ 2013; 347: f4147.
16. Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B,. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994; 94: 182-188.
17. Laforest L, Bousquet J, Pietri G, Sazonov Kocevar V, Yin D, Pacheco Y, et al. Quality of life during pollen season in patients with seasonal allergic rhinitis with or without asthma. Int Arch Allergy Immunol 2005; 136: 281-286. (Pubitemid 40529200)
18. Juniper EF, Guyatt GH,. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21: 77-83.
19. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN,. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 1999; 104: 364-369. (Pubitemid 29420434)
20. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN,. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000; 30: 132-140. (Pubitemid 30093890)
21. Juniper EF, Howland WC, Roberts NB, Thompson AK, King DR,. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol 1998; 101: 163-170. (Pubitemid 28152377)
22. Juniper EF, Guyatt GH, Dolovich J,. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994; 93: 413-423. (Pubitemid 24081781)
23. Baiardini I, Pasquali M, Giardini A, Specchia C, Passalacqua G, Venturi S, et al. Rhinasthma: a new specific QoL questionnaire for patients with rhinitis and asthma. Allergy 2003; 58: 289-294. (Pubitemid 36566745)
24. Sieber J, Gross A, Shah-Hosseini K, Mosges R,. The RHINASTHMA GAV scores without SLIT, at the beginning and at the end of seasonal SLIT. Asian Pac J Allergy Immunol 2010; 28: 232-236.
25. Braido F, Baiardini I, Stagi E, Scichilone N, Rossi O, Lombardi C, et al. RhinAsthma patient perspective: a short daily asthma and rhinitis QoL assessment. Allergy 2012; 67: 1443-1450.
26. de Graaf-in 't Veld T, Koenders S, Garrelds IM, Gerth van Wijk R,. The relationships between nasal hyperreactivity, quality of life, and nasal symptoms in patients with perennial allergic rhinitis. J Allergy Clin Immunol 1996; 98: 508-513. (Pubitemid 26377915)
27. Bousquet PJ, Combescure C, Klossek JM, Daures JP, Bousquet J,. Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol 2009; 123: 1349-1354.
28. Bousquet PJ, Combescure C, Neukirch F, Klossek JM, Mechin H, Daures JP, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 2007; 62: 367-372. (Pubitemid 46398791)
29. Juniper EF, Guyatt GH, Willan A, Griffith LE,. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47: 81-87. (Pubitemid 24034293)
30. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ,. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 1996; 98: 843-845. (Pubitemid 26357253)
31. Roder E, Berger MY, Hop WC, de Groot H, van Wijk RG,. The relevance of patient-reported outcomes in a grass pollen immunotherapy trial in children and adolescents with rhinoconjunctivitis. Pediatr Allergy Immunol 2013; 24: 39-48.
32. Jaeschke R, Singer J, Guyatt GH,. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-415. (Pubitemid 20025670)
33. Guyatt GH, Nogradi S, Halcrow S, Singer J, Sullivan MJ, Fallen EL,. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989; 4: 101-107. (Pubitemid 19081188)
34. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012; 129: 1282-1289.
35. Langley GB, Sheppeard H,. The visual analogue scale: its use in pain measurement. Rheumatol Int 1985; 5: 145-148. (Pubitemid 15007299)
36. Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P,. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. Clin Exp Allergy 2013; 43: 881-888.
37. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A,. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005; 60: 801-807. (Pubitemid 40769884)
38. Frew AJ, Powell RJ, Corrigan CJ, Durham SR,. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 319-325. (Pubitemid 43190146)
39. Kuna P, Kaczmarek J, Kupczyk M,. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. J Allergy Clin Immunol 2011; 127: 502-508.
40. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109: 251-256. (Pubitemid 34158289)
41. Worm M,. 'Well days' after sublingual immunotherapy with a high-dose 6-grass pollen preparation. Allergy 2009; 64: 1104-1105.
42. Wahn U, Klimek L, Ploszczuk A, Adelt T, Sandner B, Trebas-Pietras E, et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2012; 130: 886-893.
43. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S,. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 802-809.
44. Dahl R, Stender A, Rak S,. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61: 185-190. (Pubitemid 43381828)
45. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118: 434-440. (Pubitemid 44160721)
46. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123: 167-173.
47. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120: 1338-1345. (Pubitemid 350225683)
48. Durham SR, Birk AO, Andersen JS,. Days with severe symptoms: an additional efficacy endpoint in immunotherapy trials. Allergy 2011; 66: 120-123.
49. DuBuske LM, Frew AJ, Horak F, Keith PK, Corrigan CJ, Aberer W, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011; 32: 239-247.
50. Pfaar O, Urry Z, Robinson DS, Sager A, Richards D, Hawrylowicz CM, et al. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy 2012; 67: 272-279.
51. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129: 717-725.
52. Justicia JL, Cardona V, Guardia P, Ojeda P, Olaguibel JM, Vega JM, et al. Validation of the first treatment-specific questionnaire for the assessment of patient satisfaction with allergen-specific immunotherapy in allergic patients: the ESPIA questionnaire. J Allergy Clin Immunol 2013; 131: 1539-1546.
53. Franzke N, Schafer I, Jost K, Blome C, Rustenbach SJ, Reich K, et al. A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy 2011; 66: 665-670.
54. Nogueira-Silva L, Martins SV, Cruz-Correia R, Azevedo LF, Morais-Almeida M, Bugalho-Almeida A, et al. Control of allergic rhinitis and asthma test-a formal approach to the development of a measuring tool. Respir Res 2009; 10: 52.
55. Fonseca JA, Nogueira-Silva L, Morais-Almeida M, Sa-Sousa A, Azevedo LF, Ferreira J, et al. Control of Allergic Rhinitis and Asthma Test (CARAT) can be used to assess individual patients over time. Clin Transl Allergy 2012; 2: 16.
56. Nathan RA, Dalal AA, Stanford RH, Meltzer EO, Schatz M, Derebery J, et al. Qualitative Development of the Rhinitis Control Assessment Test (RCAT), an Instrument for Evaluating Rhinitis Symptom Control. Patient 2010; 3: 91-99.
57. Demoly P, Jankowski R, Chassany O, Bessah Y, Allaert FA,. Validation of a self-questionnaire for assessing the control of allergic rhinitis. Clin Exp Allergy 2011; 41: 860-868.
58. Dreborg S, Frew A,. Allergen standardization and skin tests. EAACI Position paper. Allergy 1993; 48 (Suppl 44): 49-82.
59. Malling H-J, Weeke B,. Immunotherapy. Position Paper of the European Academy of Allergology and Clinical Immunology (EAACI). Allergy 1993; 48 (Suppl 14): 9-35.
60. Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008; 121: 1120-1125.
61. Des Roches A, Paradis L, Knani J, Hejjaoui A, Dhivert H, Chanez P, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51: 430-433. (Pubitemid 26266386)
62. Bousquet J, Maasch H, Martinot B, Hejjaoui A, Wahl R, Michel FB,. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988; 82: 439-446.
63. Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J,. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990; 85: 460-472. (Pubitemid 20075183)
64. Moller C, Bjorksten B, Nilsson G, Dreborg S,. The precision of the conjunctival provocation test. Allergy 1984; 39: 37-41. (Pubitemid 14220454)
65. Moller C, Elsayed S,. Seasonal variation of the conjunctival provocation test, total and specific IgE in children with birch pollen allergy. Int Arch Allergy Appl Immunol 1990; 92: 306-308.
66. Sacchetti M, Micera A, Lambiase A, Speranza S, Mantelli F, Petrachi G, et al. Tear levels of neuropeptides increase after specific allergen challenge in allergic conjunctivitis. Mol Vis 2011; 17: 47-52.
67. Riechelmann H, Schmutzhard J, van der Werf JF, Distler A, Kleinjans HA,. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis. Am J Rhinol Allergy 2010; 24: e104-e109.
68. Riechelmann H, Epple B, Gropper G,. Comparison of conjunctival and nasal provocation test in allergic rhinitis to house dust mite. Int Arch Allergy Immunol 2003; 130: 51-59. (Pubitemid 36184438)
69. Haugaard L, Dahl R, Jacobsen L,. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993; 91: 709-722. (Pubitemid 23110716)
70. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468-475. (Pubitemid 29372886)
71. Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998; 351: 629-632. (Pubitemid 28098445)
72. Hellings PW, Scadding G, Alobid I, Bachert C, Fokkens WJ, Gerth van Wijk R, et al. Executive summary of European Task Force document on diagnostic tools in rhinology. Rhinology 2012; 50: 339-352.
73. Bousquet J, Hejjaoui A, Clauzel AM, Guerin B, Dhivert H, Skassa-Brociek W, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 1988; 82: 971-977. (Pubitemid 19024655)
74. Klimek L, Mewes T, Wolf H, Hansen I, Schnitker J, Mann WJ,. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity. Otolaryngol Head Neck Surg 2005; 133: 538-543. (Pubitemid 41431842)
75. Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS,. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 2009; 124: 150-156.
76. Pfaar O, Barth C, Jaschke C, Hormann K, Klimek L,. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol 2011; 154: 336-344.
77. Naclerio RM, Proud D, Moylan B, Balcer S, Freidhoff L, Kagey-Sobotka A, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997; 100: 293-300.
78. Scadding GW, Calderon MA, Bellido V, Koed GK, Nielsen NC, Lund K, et al. Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods 2012; 384: 25-32.
79. Bousquet J, Calvayrac P, Guerin B, Hejjaoui A, Dhivert H, Hewitt B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985; 76: 734-744. (Pubitemid 16249375)
80. Krug N,. Usefulness of pollen chamber in the evaluation of clinical trials with allergen products. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2006; 95: 167-170.
81. Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larche M, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013; 131: 103-109.
82. Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Devillier P, Montagut A, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009; 124: 471-477.
83. Krug N, Hohlfeld JM, Larbig M, Buckendahl A, Badorrek P, Geldmacher H, et al. Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis. Clin Exp Allergy 2003; 33: 1667-1674. (Pubitemid 38005386)
84. Hohlfeld JM, Holland-Letz T, Larbig M, Lavae-Mokhtari M, Wierenga E, Kapsenberg M, et al. Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions. Clin Exp Allergy 2010; 40: 998-1006.
85. Jacobs RL, Harper N, He W, Andrews CP, Rather CG, Ramirez DA, et al. Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes. J Allergy Clin Immunol 2012; 130: 122-127.
86. Radcliffe MJ, Lewith GT, Prescott P, Church MK, Holgate ST,. Do skin prick and conjunctival provocation tests predict symptom severity in seasonal allergic rhinoconjunctivitis? Clin Exp Allergy 2006; 36: 1488-1493. (Pubitemid 44902925)
87. Stellefson M, Dipnarine K, Stopka C,. The chronic care model and diabetes management in US primary care settings: a systematic review. Prev Chronic Dis 2013; 10: E26.
88. Bousquet J, Tanasescu CC, Camuzat T, Anto JM, Blasi F, Neou A, et al. Impact of early diagnosis and control of chronic respiratory diseases on active and healthy ageing. Allergy 2013; 68: 555-561.
89. Bousquet J, Bachert C, Canonica GW, Casale TB, Cruz AA, Lockey RJ, et al. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol 2009; 124: 428-433.
90. Hafner D, Reich K, Zschocke I, Lotzin A, Meyer H, Kettner J, et al. Prospective validation of the "rhino conjunctivitis allergy-control- SCORE(c)" (RC-ACS(c)). Clin Transl Allergy 2012; 2: 17.
91. Hafner D, Reich K, Matricardi PM, Meyer H, Kettner J, Narkus A,. Prospective validation of 'Allergy-Control-SCORE(TM) ': a novel symptom-medication score for clinical trials. Allergy 2011; 66: 629-636.
92. Grouin JM, Vicaut E, Jean-Alphonse S, Demoly P, Wahn U, Didier A, et al. The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials. Clin Exp Allergy 2011; 41: 1282-1288.
93. Braido F, Bousquet PJ, Brzoza Z, Canonica GW, Compalati E, Fiocchi A, et al. Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GALEN taskforce position paper. Allergy 2010; 65: 959-968.
94. Roberts G, Hurley C, Lack G,. Development of a quality-of-life assessment for the allergic child or teenager with multisystem allergic disease. J Allergy Clin Immunol 2003; 111: 491-497. (Pubitemid 36337867)
95. Didier A, Melac M, Montagut A, Lheritier-Barrand M, Tabar A, Worm M,. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy 2009; 64: 166-171.
96. Frolund L, Durham SR, Calderon M, Emminger W, Andersen JS, Rask P, et al. Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life. Allergy 2010; 65: 753-757.
97. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O,. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116: 608-613. (Pubitemid 41267135)
98. Demoly P, Calderon MA, Casale T, Scadding G, Annesi-Maesano I, Braun JJ, et al. Assessment of disease control in allergic rhinitis. Clin Transl Allergy 2013; 3: 7.